GfK adds payer expert Bridgehead to its roster

Timothy Fitzgerald
Timothy Fitzgerald
GfK bought market access counselor Bridgehead International for an undisclosed sum.

The consultancy now operates as GfK Bridgehead. GfK said Bridgehead generated 2011 sales of €12.12 million ($16 million).

In a statement, GfK chief operating officer Debra Pruent termed the acquisition “an important strategic investment” at a time when governments, insurance companies and other healthcare providers are stepping up use of pricing and reimbursement controls. The acquisition comes on the heels of GfK's purchase of Knowledge Networks in December.

With Bridgehead, GfK gets access to that firm's global payer panel and US online portal. In an e-mail to clients, GfK touted Bridgehead's ability to provide support in pricing, reimbursement, health economics and market access, plus its knowledge of local healthcare systems.

Timothy Fitzgerald will remain in his role as Bridgehead managing director, as will the rest of his executive team. Pharma, device and diagnostics clients, said Fitzgerald in the statement, are seeking to “hard-wire market access and payer insights into their R&D, portfolio, business development, commercialization and life cycle strategies.”

GfK also pledged to grow Bridgehead's staff of 60 and to keep US offices in Boston, San Francisco and New York City, as well as London and Melton Mowbray, UK.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.